Inhibrx Biosciences, Inc. (INBX) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
INBX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Inhibrx Biosciences, Inc. (INBX) trades at a price-to-earnings ratio of -13.8x, with a stock price of $124.52 and trailing twelve-month earnings per share of $-9.04.
The current P/E is 11149% below its 5-year average of 0.1x. Over the past five years, INBX's P/E has ranged from a low of 0.1x to a high of 0.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, INBX trades at a 162% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, INBX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our INBX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
INBX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 15.5Lowest | -Best | +1747%Best | |
| $6B | 24.8 | -Best | -34% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
INBX Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $13.99 | $116.53 | 0.1x | -4% |
| FY2024 Q4 | $15.40 | $117.89 | 0.1x | +5% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $15.66 | $119.47 | 0.1x | +5% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $14.17 | $121.21 | 0.1x | -6% |
Average P/E for displayed period: 0.1x
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INBX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINBX — Frequently Asked Questions
Quick answers to the most common questions about buying INBX stock.
Is INBX stock overvalued or undervalued?
INBX trades at -13.8x P/E, below its 5-year average of 0.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does INBX's valuation compare to peers?
Inhibrx Biosciences, Inc. P/E of -13.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is INBX's PEG ratio?
INBX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.